Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125637101 | 12563710 | 1 | I | 20160708 | 20160716 | 20160716 | EXP | US-ASTRAZENECA-2016SE74993 | ASTRAZENECA | 0.00 | F | Y | 90.70000 | KG | 20160716 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125637101 | 12563710 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 21153 | 40 | MG | CAPSULE | BID | ||||||
| 125637101 | 12563710 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 21153 | 40 | MG | CAPSULE | BID | ||||||
| 125637101 | 12563710 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | GENERIC 40 MG, TWO TIMES A DAY | U | 21153 | |||||||||
| 125637101 | 12563710 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | GENERIC 40 MG, TWO TIMES A DAY | U | 21153 | |||||||||
| 125637101 | 12563710 | 5 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 21153 | 40 | MG | CAPSULE | BID | ||||||
| 125637101 | 12563710 | 6 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 21153 | 40 | MG | CAPSULE | BID | ||||||
| 125637101 | 12563710 | 7 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | ||||||||||
| 125637101 | 12563710 | 8 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | ||||||||||
| 125637101 | 12563710 | 9 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 125637101 | 12563710 | 10 | C | TUMS | CALCIUM CARBONATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125637101 | 12563710 | 1 | Gastrooesophageal reflux disease |
| 125637101 | 12563710 | 2 | Dyspepsia |
| 125637101 | 12563710 | 3 | Gastrooesophageal reflux disease |
| 125637101 | 12563710 | 4 | Dyspepsia |
| 125637101 | 12563710 | 5 | Gastrooesophageal reflux disease |
| 125637101 | 12563710 | 6 | Dyspepsia |
| 125637101 | 12563710 | 7 | Gastrooesophageal reflux disease |
| 125637101 | 12563710 | 8 | Dyspepsia |
| 125637101 | 12563710 | 9 | Blood cholesterol abnormal |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125637101 | 12563710 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125637101 | 12563710 | Chest pain | |
| 125637101 | 12563710 | Drug effect decreased | |
| 125637101 | 12563710 | Dyspnoea | |
| 125637101 | 12563710 | Eructation | |
| 125637101 | 12563710 | Gastric mucosal lesion | |
| 125637101 | 12563710 | Off label use | |
| 125637101 | 12563710 | Oropharyngeal pain | |
| 125637101 | 12563710 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125637101 | 12563710 | 1 | 2006 | 0 | ||
| 125637101 | 12563710 | 2 | 2006 | 0 | ||
| 125637101 | 12563710 | 3 | 201510 | 0 | ||
| 125637101 | 12563710 | 4 | 201510 | 0 |